NIAID Commits $100 Million Per Year to Pandemic Preparedness Network
March 5, 2026 · 2 min read
Jared Klein
The National Institute of Allergy and Infectious Diseases is directing approximately $100 million per year to the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness Network—the largest coordinated federal investment in pre-pandemic countermeasure development since the COVID-era push to accelerate vaccine platforms.
How ReVAMPP Works
The network funds multi-year research centers conducting basic and translational research on "prototype pathogens"—representative viruses from families known to infect humans. The strategy: develop vaccines and antibodies against one well-studied virus in a family, then rapidly adapt that platform when a novel pathogen from the same family emerges.
Each ReVAMPP Center must include an administrative core, a scientific advisory board, a data management core, up to three scientific cores, and two to five interdependent research projects. RTI International serves as the network's coordination and data-sharing hub, standardizing protocols across centers.
Awards run for five years with a critical inflection point near the end of Year 3, when NIAID evaluates each center's progress against stated milestones. Funding for Years 4 and 5 depends on demonstrated results—not just publications, but tangible movement toward clinical candidates.
Industry Partnerships Are Non-Negotiable
What separates ReVAMPP from typical NIH research awards is a hard requirement: every center must establish or plan a collaboration with an industry partner providing vaccine manufacturing expertise, clinical development capabilities, and regulatory pathway knowledge. NIAID is explicitly trying to bridge the gap between academic discovery and commercial product—the "valley of death" that stalled countless promising therapeutics before COVID forced emergency workarounds.
Who Should Pay Attention
The direct beneficiaries are academic institutions with strong virology and immunology programs. But biotech startups and small pharmaceutical companies should monitor this space closely for subcontracting and industry partnership opportunities—particularly those with platform technologies in mRNA, viral vector, or monoclonal antibody manufacturing.
With the FY2026 spending bill preserving NIH at $48.7 billion and blocking proposed indirect cost caps, the funding runway for programs like ReVAMPP is secure for now. Teams exploring pandemic preparedness funding can track related opportunities on Granted. Additional context on federal biodefense funding priorities is available on the Granted blog.